{"id":470187,"date":"2021-04-01T16:33:34","date_gmt":"2021-04-01T20:33:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470187"},"modified":"2021-04-01T16:33:34","modified_gmt":"2021-04-01T20:33:34","slug":"aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/","title":{"rendered":"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

AUSTIN,\u00a0Texas, April 1, 2021<\/span> \/PRNewswire\/ — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021<\/span>. \u00a0<\/p>\n

\n Conference Details<\/b>\n <\/p>\n

Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access Day
Conference Date:\u00a0Tuesday, April 6 and Thursday, April 8<\/span>
Participants:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Michael C. Hanley<\/span>, Aeglea’s chief commercial officer<\/p>\n

Conference Name: 20th<\/sup> Annual Needham Virtual Healthcare Conference
Conference Date: Monday, April 12<\/span> through Thursday, April 15<\/span>
Presentation Date and Time: Tuesday, April 13<\/span> at 11:00 am ET<\/span>
Presenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Webcast: https:\/\/ir.aeglea.com\/events-and-presentations\/<\/a> \u00a0<\/p>\n

To access the live and archived webcast, visit the Events & Presentations<\/a> section of the Company’s website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. A replay of the webcast will be available through the Company’s website for 30 days thereafter.<\/p>\n

\n About Aeglea BioTherapeutics<\/b>\n <\/p>\n

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea’s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1\/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in 2020. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families. For more information, please visit http:\/\/aeglea.com<\/a>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Aeglea
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021-301261051.html<\/a><\/p>\n

SOURCE Aeglea BioTherapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire AUSTIN,\u00a0Texas, April 1, 2021 \/PRNewswire\/ — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021. \u00a0 Conference Details Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access DayConference Date:\u00a0Tuesday, April 6 and Thursday, April 8Participants:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Michael C. Hanley, Aeglea’s chief commercial officer Conference Name: 20th Annual Needham Virtual Healthcare Conference Conference Date: Monday, April 12 through Thursday, April 15Presentation Date and Time: Tuesday, April 13 at 11:00 am ETPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive … <\/p>\n

Continue reading “Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470187","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire AUSTIN,\u00a0Texas, April 1, 2021 \/PRNewswire\/ — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021. \u00a0 Conference Details Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access DayConference Date:\u00a0Tuesday, April 6 and Thursday, April 8Participants:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Michael C. Hanley, Aeglea’s chief commercial officer Conference Name: 20th Annual Needham Virtual Healthcare Conference Conference Date: Monday, April 12 through Thursday, April 15Presentation Date and Time: Tuesday, April 13 at 11:00 am ETPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive … Continue reading "Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T20:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021\",\"datePublished\":\"2021-04-01T20:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/\",\"name\":\"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"datePublished\":\"2021-04-01T20:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1319229\\\/Aeglea_BioTherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/","og_locale":"en_US","og_type":"article","og_title":"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 - Market Newsdesk","og_description":"PR Newswire AUSTIN,\u00a0Texas, April 1, 2021 \/PRNewswire\/ — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021. \u00a0 Conference Details Conference Name: 2021 Virtual Wells Fargo Biotech Corporate Access DayConference Date:\u00a0Tuesday, April 6 and Thursday, April 8Participants:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer and Michael C. Hanley, Aeglea’s chief commercial officer Conference Name: 20th Annual Needham Virtual Healthcare Conference Conference Date: Monday, April 12 through Thursday, April 15Presentation Date and Time: Tuesday, April 13 at 11:00 am ETPresenter:\u00a0Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive … Continue reading \"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T20:33:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021","datePublished":"2021-04-01T20:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/","name":"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","datePublished":"2021-04-01T20:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1319229\/Aeglea_BioTherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470187"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}